Numinus Wellness Inc.

Numinus Wellness Inc.

Numinus Unveils New Logo and Brand Identity

New branding unifies Numinus' presence across North America Rebranding will be accomplished in phases and completed by end of 2022 VANCOUVER, BC, June 27, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the launch of a new visual brand identity that will be applied to all Company ... Read More...

Numinus Applies for International Patent Filing of Psychedelics Production Process

Filing would offer added protection to IP already submitted to USPTO VANCOUVER, BC, June 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its subsidiary Numinus Bioscience Inc. ... Read More...

Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

VANCOUVER, BC, June 21, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New Yor... Read More...

Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind

Novamind shareholders, at a separate meeting held today, have also approved the transaction Transaction expected to be completed on or about June 10, 2022 VANCOUVER, BC, June 8, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to... Read More...

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...

Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...

Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement

Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT VANCOUVER, BC, May 10, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) today announces the mailing of its management information circular (the "Circular") and related materials for the spe... Read More...

Numinus to Participate in Maxim’s 2022 Virtual Growth Conference on March 28-30, 2022

VANCOUVER, BC, March 15, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 20... Read More...

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

VANCOUVER, BC, Feb. 28, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earli... Read More...

Numinus Wellness Inc. Graduates to the OTCQX Best Market

VANCOUVER, BC, Jan. 26, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will commence trading on the OTCQX® Best Market in the United States when the market opens tomorro... Read More...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

VANCOUVER, BC, Jan. 13, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 20... Read More...

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending th... Read More...

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients VANCOUVER, BC, Nov. 29, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compo... Read More...

Numinus Announces Departure of Stacey Wallin

VANCOUVER, BC, Nov. 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Numinus will manage two new clinics in Montreal and Vancouver to host trials. VANCOUVER, BC, Nov. 10, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has secured two new Canadian psychedelic clinics that will host the Canadian sites of the MAPS Publi... Read More...

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

VANCOUVER, BC, July 29, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its fiscal third quarter results ended May 31, 2021. In the third quarter, Numinus maintained a healthy cash position, achieve... Read More...

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

NCT's treatment of neurological disorders combined with Numinus' leadership in psychedelic-assisted therapy will offer opportunity to treat a range of chronic neurological conditions and common concurrent mental health challenges VANCOUVER, BC, July 6, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company adv... Read More...

EGF Theramed Joint Venture Partner Pharmadelic Labs Announces Lab Services Agreement With Numinus Wellness

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) ("Theramed", the "Company") is pleased to announce that its subsidiary joint venture Pharmadelic Labs Inc. ("Pharmadelic") has signed a laboratory services agreement with Numinus Wellness Inc. (TSXV: NUMI) ("Numinus").Ph... Read More...

Numinus Announces Update to Escrow Release Schedule

VANCOUVER, BC, June 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that, in relation to its graduation from Tier 2 to Tier 1 of the TSX Venture Exchange (the "Exchange"), all securities o... Read More...

Numinus Announces Grant of Stock Options

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Jan. 14, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic... Read More...

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer

Acquisition of industry-leading instrument by Thermo Fisher Scientific will significantly advance psychedelic research and accelerate third-party standardized testing capabilities VANCOUVER, BC, Jan. 13, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing an... Read More...

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

The agreement will focus on developing safe, effective, all-natural products for the emerging psychedelic industry  VANCOUVER, BC, Jan. 6, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychede... Read More...

Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Proceeds add to recently executed warrants and options of $8.9 million /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, Dec. 29, 2020 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing... Read More...

Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming

The combination further enhances Numinus' leadership position in evidence-based psychedelic-assisted psychotherapy and health solutions VANCOUVER, BC, Dec. 15, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, acces... Read More...

Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming Fran├žais

The combination further enhances Numinus' leadership position in evidence-based psychedelic-assisted psychotherapy and health solutions VANCOUVER, BC, Dec. 15, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, acces... Read More...

Numinus Wellness commends Health Canada for its intent to make MDMA and psilocybin treatment available through the Special Access Programme

 First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in need before formal drug approval  VANCOUVER, BC, Dec. 11, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, access... Read More...

Numinus Wellness Inc. Announces an Increase to the Previously Announced Bought Deal Public Offering

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./VANCOUVER, BC, Dec. 7, 2020 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and suppo... Read More...